Aspect Biosystems occupies a unique place in the biotech market, having developed a platform for in-house innovation and licensed research partnerships with academia and industry. The promise of this technology – and its platform model – could reshape the business of tissue therapeutics.
Current tissues under development in Aspect’s bio engineering pipeline include personalized liver tissue as well as a pancreatic tissue for type 1 diabetes. Aspect’s proprietary bioprinting platform is behind over 20 collaboration projects with leading pharma, biotech and research centres around the world. In 2019 Aspect announced deals with GSK, Merck and JSR.
Get our weekly email newsletter of curated insights and AI news.
© 2021 Radical Ventures Investments Inc.